Table 2.
GDF15 and NT‐proBNP and Risk of Incident Dementia
| Biomarker | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
|
HR (95% CI) |
P Value |
HR (95% CI) |
P Value |
HR (95% CI) |
P Value | |
| GDF15 | ||||||
| Per SDU increase | 1.57 (1.30–1.90) | <0.0001 | 1.54 (1.22–1.95) | 0.0004 | 1.45 (1.13–1.85) | 0.003 |
| T2 vs T1 | 1.26 (0.78–2.02) | 0.35 | 1.33 (0.82–2.16) | 0.25 | 1.28 (0.79–2.10) | 0.32 |
| T3 vs T1 | 2.49 (1.61–3.87) | <0.001 | 2.36 (1.45–3.83) | <0.001 | 2.16 (1.31–3.56) | 0.003 |
| NT‐proBNP | ||||||
| Per SDU increase | 1.40 (1.14–1.71) | 0.001 | 1.32 (1.05–1.65) | 0.02 | 1.25 (0.99–1.56) | 0.06 |
| T2 vs T1 | 0.89 (0.56–1.41) | 0.61 | 0.79 (0.49–1.28) | 0.34 | 0.75 (0.47–1.21) | 0.24 |
| T3 vs T1 | 1.82 (1.20–2.75) | 0.005 | 1.62 (1.03–2.55) | 0.04 | 1.43 (0.90–2.28) | 0.13 |
Model 1, adjusted for age and sex. Model 2, adjusted for age, sex, education, systolic blood pressure, use of antihypertensive medication, body mass index, current smoking, estimated glomerular filtration rate, prevalent diabetes mellitus, prevalent cardiovascular disease, and apolipoprotein E4 carrier status. Model 3, model 2+adjustment for GDF15 (NT‐proBNP analysis) and NT‐proBNP (GDF15 analysis). GDF15 and NT‐proBNP were natural logarithmically transformed and standardized. GDF15 indicates growth differentiation factor 15; HR, hazard ratio; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; SDU, SD unit; T1, tertile 1; T2, tertile 2; and T3, tertile 3.